DAPT Duration - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy
P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial
A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial
Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI)
Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial

Consensus

2018 May;20(Suppl F):F1-F74.

JOURNAL：

Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease

Gulizia MM, ESC Scientific Document Group; Faculty for approval of the Consensus Document.

2576

Keywords: Coronary artery disease; Dual antiplatelet therapy; Long-term dual antiplatelet therapy; Prior myocardial infarction

ABSTRACT